Vyome to go public and trade on the Nasdaq Capital Market under the ticker symbol “HIND”
July 09, 2024 12:13 ET
|
Vyome Therapeutics Inc.
CAMBRIDGE, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Vyome Therapeutics, a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large...
ReShape Lifesciences® Enters Into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
July 09, 2024 08:31 ET
|
ReShape Lifesciences Inc
ReShape and Vyome, a Clinical Stage Specialty Pharmaceutical Company Working To Treat Immuno-Inflammatory Diseases of Unmet Need, to Combine in All-Stock Merger ReShape to Sell its Assets to...
Eureka Acquisition Corp Announces Closing of $50 Million Initial Public Offering
July 03, 2024 13:31 ET
|
Eureka Acquisition Corp
Shanghai, July 03, 2024 (GLOBE NEWSWIRE) -- Eureka Acquisition Corp (the “Company”), a blank check company incorporated as a Cayman Islands exempted company today announced the closing of its...
Eureka Acquisition Corp Announces Pricing of $50 Million Initial Public Offering
July 02, 2024 09:00 ET
|
Eureka Acquisition Corp
Shanghai, July 02, 2024 (GLOBE NEWSWIRE) -- Eureka Acquisition Corp (the “Company”), a blank check company incorporated as a Cayman Islands exempted company and led by Chairman and Chief Executive...
Nexalin Technology Announces Closing of $5.2 Million Public Offering
July 01, 2024 14:45 ET
|
Nexalin Technology, Inc.
HOUSTON, TX, July 01, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today announced the closing of its previously announced public offering of...
Nexalin Technology Announces Pricing of $5.2 Million Public Offering
June 27, 2024 21:15 ET
|
Nexalin Technology, Inc.
HOUSTON, TX, June 27, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today announced the pricing of a public offering of 3,000,000 shares of...
Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
June 27, 2024 08:00 ET
|
Rezolute, Inc.
NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative...
Kraig Biocraft Laboratories Increases Spider Silk Production with Next Generation of Hybrid Eggs Completed
June 25, 2024 07:05 ET
|
Kraig Biocraft Laboratories
Kraig Labs (OTCQB: KBLB) expanded its production of spider silk with the creation of the next generation of BAM-1 hybrid
Kaival Brands Announces Closing of $6.0 Million Public Offering
June 24, 2024 16:05 ET
|
Kaival Brands Innovations Group, Inc.
GRANT-VALKARIA, Fla., June 24, 2024 (GLOBE NEWSWIRE) -- Kaival Brands Innovations Group, Inc., (NASDAQ: KAVL) (“Kaival Brands”, the “Company”), the exclusive U.S. distributor of all products...
ALIM Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Alimera Sciences to ANI Pharmaceuticals
June 24, 2024 09:21 ET
|
Wohl & Fruchter LLP
We are investigating the fairness of the proposed sale of Alimera Sciences to ANI Pharmaceuticals for $5.50 per share in cash, plus a CVR.